Could cause temporary or reversible harm; serious harm is unlikely.
Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life stability interval, wherein the dissolution results do not comply with L3 stage dissolution criteria.
| Brand name | THEOPHYLLINE |
| Generic name | THEOPHYLLINE |
| Active ingredient(s) | THEOPHYLLINE ANHYDROUS |
| Distributed by / for | Glenmark Pharmaceuticals Inc. USA, Mahwah, NJ |
| NDC | 68462-380-01 |
| Full product label | Theophylline extended-release tablets 400mg, 100-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Limited, Colvale-Bardez, Goa- 403513 India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, Mahwah, NJ, NDC 68462-380-01 |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA |
| Distribution | USA nationwide. |
| Quantity | 22,656 bottles |
| Recall initiated | 2025-08-08 |
| Report date | 2025-08-20 |
| Recall completed | — |
| Recall number | D-0583-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Mahwah NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗